This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2015 May;14(5):460-1.

doi: 10.1016/S1474-4422(15)00016-2. Epub 2015 Apr 1.

Multiple sclerosis drugs: how much bang for the buck?

Olaf Stüve¹, Gary R Cutter²

Affiliations

Affiliations

¹ Neurology Section, VA North Texas Health Care System, Medical Service Dallas, VA Medical Center, Dallas, TX 75216, USA; Department of Neurology and Neurotherapeutics University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA; Department of Neurology, Klinikum rechts der Isar, Technische Universität München, Germany. Electronic address: olaf.stuve@utsouthwestern.edu.
² Department of Biostatistics, Section on Research Methods and Clinical Trials, University of Alabama at Birmingham, AL, USA.

PMID: 25841666
DOI: 10.1016/S1474-4422(15)00016-2

Comment

Multiple sclerosis drugs: how much bang for the buck?

Olaf Stüve et al. Lancet Neurol. 2015 May.

. 2015 May;14(5):460-1.

doi: 10.1016/S1474-4422(15)00016-2. Epub 2015 Apr 1.

Authors

Olaf Stüve¹, Gary R Cutter²

Affiliations

¹ Neurology Section, VA North Texas Health Care System, Medical Service Dallas, VA Medical Center, Dallas, TX 75216, USA; Department of Neurology and Neurotherapeutics University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA; Department of Neurology, Klinikum rechts der Isar, Technische Universität München, Germany. Electronic address: olaf.stuve@utsouthwestern.edu.
² Department of Biostatistics, Section on Research Methods and Clinical Trials, University of Alabama at Birmingham, AL, USA.

PMID: 25841666
DOI: 10.1016/S1474-4422(15)00016-2

No abstract available

PubMed Disclaimer

Comment on

Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator.
Palace J, Duddy M, Bregenzer T, Lawton M, Zhu F, Boggild M, Piske B, Robertson NP, Oger J, Tremlett H, Tilling K, Ben-Shlomo Y, Dobson C. Palace J, et al. Lancet Neurol. 2015 May;14(5):497-505. doi: 10.1016/S1474-4422(15)00018-6. Epub 2015 Apr 1. Lancet Neurol. 2015. PMID: 25841667

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science